Novel Nanoparticle-Based Cancer Treatment Shows Promise in Preclinical Studies

Strategic Insights -

Researchers from Chettinad Hospital and Research Institute in Tamil Nadu, India, have investigated the potential of a novel nanoparticle-based cancer treatment in a recent study. The treatment, which combines cerium oxide nanoparticles with the anticancer drug doxorubicin, has shown promising results in preclinical studies, inhibiting the growth of cancer cells and reducing angiogenesis.

Key Takeaways:

  • The synergistic effect of cerium oxide nanoparticles and doxorubicin encased in a polymeric nano matrix of chitosan and alginate inhibited the migration of skin cancer cells (A375) and lung cancer cells (A549) by 50-70%.
  • The treatment also exhibited anti-angiogenesis in an in-ovo model, reducing blood vessel formation by 30-40%.
  • The anticancer effect of the treatment was evident in Swiss albino mice with melanoma, with 80-90% reduction in tumor size after 21 days of treatment.
  • Histopathological analysis of the cancer tissue showed complete neutralization of melanoma symptoms in animals.
  • The combination of cerium oxide and doxorubicin demonstrated a higher therapeutic effect in cancer cells and animals than individual drugs.
  • Future studies may extrapolate this research to other cancer models in animals.
  • This research has been peer-reviewed and published in the journal ChemNanoMat in 2025.

Statistics:

  • The treatment inhibited skin cancer cell migration by 50-70%.
  • The treatment reduced lung cancer cell migration by 50-70%.
  • The treatment reduced blood vessel formation in an in-ovo model by 30-40%.
  • The treatment reduced tumor size in Swiss albino mice with melanoma by 80-90%.
  • The combination of cerium oxide and doxorubicin demonstrated a 20-30% higher therapeutic effect than individual drugs.

Sources:

  • NewsRx. Investigators from Chettinad Hospital and Research Institute Target Cancer (Assessing the Anticancer Potential of Cerium Oxide Nanoparticles With Doxorubicin In a Polymeric Nanomatrix: Histopathological and Antiangiogenic Insights). Health & Medicine Week. July 18, 2025; p 2107.